Long-Term Efficacy and Tolerance of Efavirenz- and Nevirapine-Containing Regimens in Adult HIV Type 1 Senegalese Patients
- 1 June 2008
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 24 (6), 753-760
- https://doi.org/10.1089/aid.2007.0295
Abstract
Owing to their low toxicity, low price, and ease of use, efavirenz (EFV) and nevirapine (NVP) are frequently used as part of antiretroviral regimens for AIDS treatment. Several clinical trials have already studied their efficacy and tolerance. However, long-term observations of the effects of these drugs in patients are limited. We used data from a prospective Senegalese cohort to analyze long-term tolerance and efficacy of these two drugs in a low-resources setting. Patients were included if they started their therapy with EFV or NVP. They were censored after treatment discontinuation. The primary endpoint was the time to treatment discontinuation. Secondary endpoints included time to death, time to disease progression, occurrence of severe adverse effects, CD4 cell recovery, and virological response. Confounding factors were controlled using marginal structural models. The median follow-up time in both EFV and NVP arms was 48 months. The hazard ratio (HR) of drug discontinuation in the EFV arm vs. the NVP arm was 0.84 (0.34; 1.87). There was a borderline difference in virological response [HR = 1.38 (0.999; 1.89)] but no differences in time to death [HR = 1.15 (0.41; 3.24)], time to AIDS progression [HR = 1.25 (0.61; 2.58)], or time to increase in CD4 cell count above 500 cells/mm3. Adverse effects were different between NVP and EFV, but long-term tolerance was good for both. This analysis provided further information on long-term tolerance and efficacy of EFV and NVP in a resource-limited setting.Keywords
This publication has 30 references indexed in Scilit:
- An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adultsAIDS, 2006
- Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort studyAIDS, 2006
- Clinical, Virologic, and Immunologic Response to Efavirenz-or Protease Inhibitor???Based Highly Active Antiretroviral Therapy in a Cohort of Antiretroviral-Naive Patients With Advanced HIV Infection (EfaVIP 2 Study)JAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
- Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 InfectionThe New England Journal of Medicine, 2003
- Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte dʼIvoireAIDS, 2003
- A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patientsAIDS, 2003
- Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in SenegalAIDS, 2003
- Comparison of Nevirapine- and Efavirenz-Containing Antiretroviral Regimens in Antiretroviral-Naïve Patients: A Cohort StudyHIV Research & Clinical Practice, 2002
- The Tolerability of Efavirenz after Nevirapine-Related Adverse EventsClinical Infectious Diseases, 2000
- Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in AdultsThe New England Journal of Medicine, 1999